Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity by Max Cigrang, Julian Obid, Maguelone Nogaret, Léane Seno, Tao Ye, Guillaume Davidson, Philippe Catez, Pietro Berico, Clara Capelli, Clara Marechal, Amélie Zachayus, Clémence Elly, Marie Jose Guillen Navarro, Marta Martinez Diez, Gema Santamaria Nunez, Tsai-Kun Li, Emmanuel Compe, Pablo Avilés, Irwin Davidson, Jean-Marc Egly, Carmen Cuevas, Frédéric Coin

“…These findings extend to other cancers, like small cell lung cancer, recently approved for ecteinascidin-based treatment. …”
Get full text

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings by Benjamin Izar, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Anjali Saqi, Catherine A Shu, Katja Schulze, Brian S Henick, Naiyer A Rizvi, Samyukta Mallick, Yohanna Georgis, Peter D Koch, Stephanie Izard, Robert F Garofano, Cheryl V Wong, Jessica Grindheim, Joshua R Sonett, Alison M Taylor

“…Introduction Neoadjuvant chemoimmunotherapy has achieved overall survival (OS) benefit for patients with resectable non-small cell lung cancer (NSCLC). Here, we present outcomes after 3 years of follow-up from the first reported study of neoadjuvant atezolizumab+chemotherapy.Methods This open-label, multicenter single-arm investigator-initiated phase II study conducted at three US hospitals tested up to four cycles of atezolizumab, carboplatin, and nab-paclitaxel prior to surgery. …”
Get full text

A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy by CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran

“…Inclusion criteria: ① Patients who were pathologically confirmed to have malignant tumors (lung cancer breast cancer or esophageal cancer); ② patients with radiation therapy indications as recommended by the guidelines; ③ patients with an ECOG score of 0-1; ④ patients with no significant abnormalities in electrocardiogram and echocardiography results. …”
Get full text

Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC by Domenico Lo Tartaro, Beatrice Aramini, Valentina Masciale, Nikolaos Paschalidis, Francesco Demetrio Lofaro, Anita Neroni, Rebecca Borella, Elena Santacroce, Alin Liviu Ciobanu, Anna Valeria Samarelli, Federica Boraldi, Daniela Quaglino, Alessandra Dubini, Michele Gaudio, Gloria Manzotti, Francesca Reggiani, Federica Torricelli, Alessia Ciarrocchi, Antonino Neri, Federica Bertolini, Massimo Dominici, Pier Luigi Filosso, Franco Stella, Lara Gibellini, Sara De Biasi, Andrea Cossarizza

“…Abstract B cells have emerged as central players in the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC). However, although there is clear evidence for their involvement in cancer immunity, scanty data exist on the characterization of B cell phenotypes, bioenergetic profiles and possible interactions with T cells in the context of NSCLC. …”
Get full text

Use of inpatient palliative care in metastatic testicular cancer patients undergoing critical care therapy: insights from the national inpatient sample by Cristina Cano Garcia, Reha-Baris Incesu, Francesco Barletta, Simone Morra, Lukas Scheipner, Andrea Baudo, Stefano Tappero, Mattia Luca Piccinelli, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Carlo Terrone, Ottavio De Cobelli, Luca Carmignani, Sascha Ahyai, Nicola Longo, Derya Tilki, Alberto Briganti, Severine Banek, Luis A. Kluth, Felix K. H. Chun, Pierre I. Karakiewicz

“…However, this rates remain lower compared to metastatic lung cancer patients, indicating the need for further awareness among clinicians treating metastatic testicular cancer. …”
Get full text

Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital by Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeon Park, Gheeyoung Choe, Jee Hyun Kim, Jin-Haeng Chung

“…Of patients with tier I variants, 13.7% received NGS-based therapy as follows: Thyroid cancer (2/7, 28.6%), skin cancer (2/8, 25.0%), gynecologic cancer (7/65, 10.8%), and lung cancer (12/112, 10.7%). Of 32 patients with measurable lesions who received NGS-based therapy, 12 (37.5%) achieved a partial response, and 11 (34.4%) achieved stable disease. …”
Get full text

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study by Adeline Ruyssen-Witrand, Jacques-Eric Gottenberg, Philippe Dieude, Rene-Marc Flipo, Jerome Avouac, Emanuelle Dernis, Anne Tournadre, Marie-Elise Truchetet, Raphaele Seror, André Ramon, Nicolas Roux, André Basch, Pascal Chazerain, Fabienne Coury-Lucas, Richard Damade, Pierre-Antoine Juge, Thao Pham, Clément Prati, Olivier Brocq, Jean Hugues Salmon, Christian hubert roux, Félicien Triboulet, Charles Leské, Émilie Shipley

“…Only one acute regressive exacerbation of ILD was noted, and no lung cancer was diagnosed. No deaths occurred. JAKi was discontinued in 17 patients including 8 for inefficacy on joint involvement and 5 for intolerance.Conclusion The analysis indicates stability of RA-ILD in patients treated with JAKi. …”
Get full text

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors by Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD

“…Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical, pathologic, and demographic variables from five institutions for patients whose tumors met criteria for SMARCA4-UTs (undifferentiated phenotype and loss of SMARCA4 (BRG1) by immunohistochemistry). …”
Get full text

FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma by Xuejuan Gao, Donglan Huang, Ying Liu, Gui Zhang, Xiaofen Zheng, Baiye Guan, Aiwen Chen, Jiayao Wu, Shi-Ming Luo, Zonghua Liu, Luxuan Chen, Xiaohui Liu, Jingjie Jin, Xingfeng Yin, Zhenghua Sun, Yunfang Zhang, Meizhi Lu, Gong Zhang, Wanting Liu, Langxia Liu

“…In conclusion, our study indicates that FAM210B is an important suppressor of cellular viability and mobility during lung cancer progression.…”
Get full text

ERBB4 selectively amplifies TGF-β pro-metastatic responses by Peihong Luo, Huanyu Hong, Baoling Zhang, Jie Li, Shuyi Zhang, Chaomin Yue, Jin Cao, Jia Wang, Yuhan Dai, Qingqing Liao, Pinglong Xu, Bing Yang, Xia Liu, Xia Lin, Yi Yu, Xin-Hua Feng

“…These selective effects facilitate lung cancer metastasis in mouse models. This discovery sheds light on the previously unrecognized role of SMAD4 as a substrate of ERBB4 and highlights the selective involvement of the ERBB4-SMAD4 regulatory axis in tumor metastasis.…”
Get full text

A Global Survey of Self-Reported Cancer Screening Practices by Health Professionals for Kidney Transplant Candidates and Recipients by Nida Saleem, Nida Saleem, Nida Saleem, Wai H. Lim, Wai H. Lim, Jacqueline H. Stephens, Jacqueline H. Stephens, Annabelle Wilson, Billie Bonevski, Allison Jaure, Allison Jaure, Armando Teixeira-Pinto, Armando Teixeira-Pinto, Eleonora Dal Grande, Eleonora Dal Grande, Martin Howell, Martin Howell, Farzaneh Boroumand, Farzaneh Boroumand, Anita van Zwieten, Anita van Zwieten, Chandana Guha, Chandana Guha, Nicole Scholes-Robertson, Nicole Scholes-Robertson, Steven J. Chadban, Steven J. Chadban, Carmel M. Hawley, Carmel M. Hawley, Jonathan C. Craig, Jeremy R. Chapman, Danyal Hassan, Greg Knoll, Greg Knoll, Naoka Murakami, Germaine Wong, Germaine Wong, Germaine Wong

“…About 85% recommended lung cancer screening for higher-risk individuals. Skin cancer screening recommendations varied from 69% for transplant candidates and 84% for recipients. …”
Get full text

Multi-cancer early detection tests for general population screening: a systematic literature review by Ros Wade, Sarah Nevitt, Yiwen Liu, Melissa Harden, Claire Khouja, Gary Raine, Rachel Churchill, Sofia Dias

“…One study of Galleri had high sensitivity for detecting lung cancer, leading to opposing findings depending on whether lung cancer was considered to be covered by existing available screening programmes or not. …”
Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. …”
Get full text

Tiptoeing on Metastatic Adenocarcinoma of the Lung by Arupreet Kochar, Harrison D. Winters, Li Zhang, Bin Zhang, Kamia Thakur, Rajesh Essrani

“…Lung cancer remains the top cause of cancer-related death in the United States. …”
Get full text

An appropriate DNA input for bisulfite conversion reveals LINE-1 and Alu hypermethylation in tissues and circulating cell-free DNA from cancers. by Trang Thi Quynh Tran, Tung The Pham, Than Thi Nguyen, Trang Hien Do, Phuong Thi Thu Luu, Uyen Quynh Nguyen, Linh Dieu Vuong, Quang Ngoc Nguyen, Son Van Ho, Hang Viet Dao, Tong Van Hoang, Lan Thi Thuong Vo

“…Using the minuscule DNA amount of 0.5 ng, much less than what has been used and recommended so far (500 ng-2 μg) or 1 μL of cfDNA extracted from 1 mL of blood, we revealed hypermethylation of LINE-1 and Alu in 407 tumour samples of primary breast, colon and lung cancers when compared with the corresponding pair-matched adjacent normal tissue samples (P < 0.05-0.001), and in cfDNA from 296 samples of lung cancers as compared with 477 samples from healthy controls (P < 0.0001). …”
Get full text

Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Trac... by Saad Qadwai, Tayyaba Rehman, Jonathan Barsa, Zeeshan Solangi, Edward Lebovics

“…Based on this review, HCV might be associated with an increased risk of renal cell and lung cancers.…”
Get full text

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment by Bassel Alsaed, Linh Lin, Jieun Son, Jiaqi Li, Johannes Smolander, Timothy Lopez, Pinar Ö. Eser, Atsuko Ogino, Chiara Ambrogio, Yoonji Eum, Tran Thai, Haiyun Wang, Eva Sutinen, Hilma Mutanen, Hanna Duàn, Nina Bobik, Kristian Borenius, William W. Feng, Behnam Nabet, Satu Mustjoki, Sanna Laaksonen, Benjamin K. Eschle, Michael J. Poitras, David Barbie, Ilkka Ilonen, Prafulla Gokhale, Pasi A. Jänne, Heidi M. Haikala

“…Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges. …”
Get full text

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2 by Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima

“…The Kirsten rat sarcoma (KRAS) oncogene was considered “undruggable” until the development of sotorasib, a KRASG12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRASG12D inhibitor, has shown promising results in basic research, although its effects against pancreatic cancer are limited when used alone. …”
Get full text

Genome analysis uncovers an inverse correlation between alterations in P21‐activated kinases and patient survival across multiple cancer types by Jessie M. Vo, Linh M. La, Ananda V. Anderson, Abdulaziz H. Alanazi, Payaningal R. Somanath

“…In pancreatic and lung cancers, although a trend of poorer survival with PAK alterations was observed, it was not statistically significant. …”
Get full text

In Vitro and In Vivo Characterization of Three Ga- and In-Labeled Peptides for Cholecystokinin Receptor Imaging by Susan Roosenburg, Peter Laverman, Lieke Joosten, Annemarie Eek, Floris P.J.T. Rutjes, Floris L. van Delft, Otto C. Boerman

“…Cholecystokinin (CCK) receptors are overexpressed in several human tumor types, such as medullary thyroid carcinomas and small cell lung cancers. Several ligands for the CCK2 receptor (CCK2R) have been developed for radionuclide targeting of these tumors. …”
Get full text